Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.45 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ITGAM | P11215 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213411 | 0.84 | ITGB3 (0.59) | ITGB3ITGA2B | |
| SCHEMBL7219492 | 0.79 | F10 (0.45) | F2F10PRSS1ITGB3ITGA2B | |
| SCHEMBL29373935 | 0.75 | ITGB3 (0.71) | ITGB3ITGA2B | |
| SCHEMBL7375616 | 0.75 | ITGB3 (0.59) | F2F10ITGB3ITGA2BMIF | |
| SCHEMBL9030900 | 0.67 | F2 (0.58) | F2F10PRSS1ITGB3ITGA2B | |
| SCHEMBL20335089 | 0.62 | NPSR1 (0.53) | MMP2MMP13SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL20335087 | 0.62 | NPSR1 (0.53) | MMP2MMP13SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL7219528 | 0.62 | ITGB3 (0.83) | ITGB3ITGA2B | |
| SCHEMBL4163332 | 0.60 | LMNA (0.51) | — | |
| SCHEMBL12556241 | 0.59 | MIF (0.74) | F2F10PRSS1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6185453-B1 | IONTOPHORETIC DEVICE INCLUDING SPECIFIED INTEGRIN INHIBITORS SUCH AS N3-(2-(3-(4-FORMAMIDINOPHENYL)-ISOXAZOLIN-5(R,S)-YL)-ACETYL)-N2 -(PHENYLSULFONYL)-2,3-(S)-DIAMINOPROPANOIC ACID | DUPONT PHARMACEUTICALS COMPANY | 2001-02-06 | — | — | US | claimed |
| EP-0730590-B1 | ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-01-17 | — | — | EP | claimed |
| WO-1996038426-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-05 | — | — | WO | claimed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | claimed |
| US-20020132276-A1 | FACS method for detecton of GPIIb/IIIa inhibitor dependent activators in plasma samples | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-09-19 | — | — | US | disclosed |
| US-20020081624-A1 | DETECTION OF PATIENTS AT RISK FOR DEVELOPING INTEGRIN ANTAGONIST/ AGONIST MEDIATED DISEASE STATES | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-06-27 | — | — | US | disclosed |
| US-6185453-B1 | IONTOPHORETIC DEVICE INCLUDING SPECIFIED INTEGRIN INHIBITORS SUCH AS N3-(2-(3-(4-FORMAMIDINOPHENYL)-ISOXAZOLIN-5(R,S)-YL)-ACETYL)-N2 -(PHENYLSULFONYL)-2,3-(S)-DIAMINOPROPANOIC ACID | DUPONT PHARMACEUTICALS COMPANY | 2001-02-06 | — | — | US | disclosed |
| EP-0730590-B1 | ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | DU PONT PHARM CO (US) | 2001-01-17 | — | — | EP | disclosed |
| EP-0970950-A2 | Novel isoxazoline and isoxazole fibrinogen receptor antagonists | DuPont Pharmaceuticals Company (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1995014683-A1 | NOVEL ISOXAZOLINE AND ISOXAZOLE FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |